AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05847517
Drug: saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dilution of 0.9% sodium chloride in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure below 110 mmHg or heart rate below 60 bpm, the infusion shall be stopped and the infusion noted.
Trial: NCT06478719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT04678323
Drug: Lifestyle Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive lifestyle management.
Trial: NCT06692166
Drug: 9MW2821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
Trial: NCT06692166
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 or 1.25 mg/m \^2 topotecan by intravenous infusion on days 1 to 5 or 1000 mg/m \^2 gemcitabine by intravenous infusion on days 1 and 8 or 500 mg/m \^2 pemetrexed by intravenous infusion on day 1 of every 21 days
Trial: NCT05445479
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient with doxycycline treatment during COVID-19 waves
Trial: NCT04509102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
Trial: NCT06430385
Drug: ION440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ION440 will be administered by intrathecal bolus (ITB) injection.
Trial: NCT04855747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT06540326
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab
Trial: NCT05853120
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
Trial: NCT06408298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive tablet
Trial: NCT05682352
Drug: LEO 158968
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion or SC injection
Trial: NCT05682352
Drug: LEO 158968
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT05682352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT05683184
Drug: [11C]OMAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
Trial: NCT04566991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
Trial: NCT06012708
Drug: KN510 60mg/day + KN713 60mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily with 28 days (4 weeks) as one cycle.
Trial: NCT06012708
Drug: KN510 120mg/day + KN713 60mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily with 28 days (4 weeks) as one cycle.
Trial: NCT06012708
Drug: KN510 120mg/day + KN713 90mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily with 28 days (4 weeks) as one cycle.
Trial: NCT06012708
Drug: KN510 120mg/day + KN713 120mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily with 28 days (4 weeks) as one cycle.
Trial: NCT04486157
Drug: IN-A012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.
Trial: NCT04486157
Drug: Akynzeo 300Mg-0.5Mg Capsule
RxNorm normalized name: Akynzeo 300mg-0.5mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be administrated Akynzeo by Orally with water.
Trial: NCT04266275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.
Trial: NCT05773820
Drug: WJB001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts.
Trial: NCT05888844
Drug: INCB099280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm description.
Trial: NCT05430035
Drug: HIPEC
RxNorm normalized name: Hyperthermic Intraperitoneal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
Trial: NCT04980222
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 50 mg/m2 body surface area of doxorubicin IV as per schedule specified in the treatment arm.
Trial: NCT05088460
Drug: REGN4461
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Trial: NCT05088460
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
Trial: NCT04980222
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 750 mg/m2 body surface area of cyclophosphamide IV as per schedule specified in the treatment arm.
Trial: NCT06389942
Drug: 9MW3011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenously on day 1
Trial: NCT06454266
Drug: ORM regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects received ORM regimen treatment every 21 days for a total of 6 cycles. The specific medication is as follows  Obutinib tablets 150mg qd d1-21 (suspended 2 days before MTX use until MTX drops to safe concentration) Rituximab 375mg/m2, d1 Methotrexate 3g/m2, d2
Trial: NCT06558071
Drug: Galatonol 300 mg/Striatin 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 film-coated caplet of Herba Asimor, twice daily
Trial: NCT06558071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 film-coated caplet of placebo Herba Asimor, twice daily
Trial: NCT05064878
Drug: Matching ZX008 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching ZX008 placebo is supplied as an oral solution.
Trial: NCT05929937
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)
Trial: NCT05496595
Drug: DCBY02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
Trial: NCT05358249
Drug: JDQ443
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRAS G12C inhibitor, oral
Trial: NCT06492031
Drug: Glucose Peritoneal Dialysis Solution
RxNorm normalized name: glucose Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
Trial: NCT05523687
Drug: [14C]-PC14586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, oral dose of \[14C\]-PC14586
Trial: NCT05446480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.
Trial: NCT06486662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
Trial: NCT06347874
Drug: Cryoablation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an injection of 1ml of 1% lidocaine per rib and ultrasound guided cryoablation of the intercostal nerves
Trial: NCT06347874
Drug: ESP Catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an ultrasound guided erector spinae plane catheter with initial bolus of 30 mL of 0.25% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour via programmed intermittent bolus.
Trial: NCT05569382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration
Trial: NCT06528496
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is an anthracycline antibiotic
Trial: NCT05162755
Drug: S095029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
Trial: NCT05365581
Drug: ASP2138
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously or Subcutaneously
Trial: NCT05365581
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously
Trial: NCT05365581
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously
Trial: NCT06504381
Drug: DB107-FC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally (PO)
Trial: NCT06786689
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: weekly single dose of tab azathioprine 300mg
Trial: NCT06237335
Drug: RCT2100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer
Trial: NCT06237335
Drug: RCT2100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks
Trial: NCT06237335
Drug: RCT2100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks
Trial: NCT05081882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants on this arm will take one placebo capsule orally three times daily for 28 days.
Trial: NCT04011839
Drug: Levobupivacaïne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of Levobupivacaïne instead ropivacaïne
Trial: NCT04983173
Drug: Ovarian Stimulation with CC+rFSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: : CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
Trial: NCT04983173
Drug: Ovarian Stimulation with rFSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
Trial: NCT06057922
Drug: YL201 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle; and at dose levels of 1.0 mg/kg and 1.2 mg/kg administered on Days 1 and 8 of each Q3W treatment cycle.
Trial: NCT04700527
Drug: Short Chain Fatty Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take the supplement as prescribed to determine if it can help with GI toxicity
Trial: NCT04700527
Drug: Tapioca Flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants taking this will be used as a control group compared to those receiving the SCFA supplement
Trial: NCT04816877
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
Trial: NCT06510257
Drug: Placebo tablet of Reconyl
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of placebo Reconyl, 3 times daily
Trial: NCT06413537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06494995
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine metronomic chemotherapy
Trial: NCT06012929
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 is an oral medication given once per week
Trial: NCT05954143
Drug: BDC-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.
Trial: NCT06563245
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2/dose,
Trial: NCT06563245
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2/dose
Trial: NCT06563245
Drug: Bedamustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
Trial: NCT05092451
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT05092451
Drug: CAR.70/IL15-transduced CB-NK cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06402331
Drug: FPI-2265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSMA ligand radiolabeled with Ac225
Trial: NCT05614752
Drug: Fexuprazan
RxNorm normalized name: fexuprazan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexuclue Tablet 40mg
Trial: NCT06295796
Drug: MK-8527
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06041789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil placebo tablet
Trial: NCT06245551
Drug: Placebo metered-dose inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo aerosol for inhalation, single dose (given as 2 actuations)
Trial: NCT05286970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal subcutaneous injection
Trial: NCT03590821
Drug: Celecoxib 200mg capsule
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily administration of celecoxib
Trial: NCT05900531
Drug: K-757
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT05900531
Drug: Matching placebo to K-757 and matching placebo to K-833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both administered orally
Trial: NCT05900531
Drug: K-757 and K-833
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both administered orally
Trial: NCT06702345
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral clindamycin pretreatment, 3 times a day 600mg, given the five days before toxigenic C. difficile exposure
Trial: NCT06701760
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of sodium chloride
Trial: NCT05676463
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive SOC ADT
Trial: NCT06703970
Drug: Corticosteroid Injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
Trial: NCT06195267
Drug: Blank control
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients only received standard treatment and care.
Trial: NCT05824975
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
Trial: NCT03904498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT06553547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo solution
Trial: NCT06205095
Drug: Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
RxNorm normalized name: factor VIII, human / von Willebrand factor, human Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
Trial: NCT06329141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT05483998
Drug: TLC-2716
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC-2716
Trial: NCT05995535
Drug: LFX/PGB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg
Trial: NCT05995535
Drug: LFX/PLA-PGB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg
Trial: NCT06797960
Drug: Intra articular injection of HA
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra articular injection of HA
Trial: NCT05353829
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration